Haleon plc (HLN.L) LSE

372.30

+0.2(+0.05%)

Updated at December 24 12:35PM

Currency In GBp

Haleon plc

Address

Building 5

Weybridge, KT13 0NY

United Kingdom of Great Britain and Northern Ireland

Phone

44 1932 822000

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

24561

First IPO Date

July 18, 2022

Key Executives

NameTitlePayYear Born
Brian James McNamaraChief Executive Officer & Executive Director3.02M1966
Dawn Amanda AllenCFO & Director972,0001968
Adrian Charles MorrisGeneral Counsel01967
Filippo LanziPresident of EMEA & LatAm0N/A
Keith ChoyPresident of Asia Pacific01969
Claire DicksonChief Digital & Technology Officer0N/A
Joanne RussellHead of Investor Relations0N/A
Line De DeckerChief Human Resources Officer01974
Lisa PaleyPresident of North America01967
Tamara RogersChief Marketing Officer01970

Description

Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.